Statin-induced myotoxicity: Pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular Reference to pitavastatin

Medicine & Life Sciences

• pitavastatin 100%
• Myotoxicity 99%
• Rhabdomyolysis 79%
• Hydroxymethylglutaryl-CoA Reductase Inhibitors 61%
• Pharmacokinetics 48%
• Drug Interactions 11%
• Cytochrome P-450 Enzyme System 11%
• Hepatocytes 9%
• Pharmaceutical Preparations 9%
• 3-hydroxy-3-methylglutaryl-coenzyme A 7%
• Myositis 7%
• Cytochrome P-450 CYP3A 6%
• Metabolome 6%
• Anions 6%
• Hypercholesterolemia 5%
• Dyslipidemias 5%
• Oxidoreductases 5%
• Renal Insufficiency 5%